Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 50afeedea6f4d21b77faff4d90903c5617706ef7
First added on: Feb 11, 2025